guest ::
| Home > Publications Database > Impact of low-value medications on quality of life, hospitalization and costs - A longitudinal analysis of patients living with dementia. > print |
| Home > Publications Database > Impact of low-value medications on quality of life, hospitalization and costs - A longitudinal analysis of patients living with dementia. > print |
| 001 | 258697 | ||
| 005 | 20240112171702.0 | ||
| 024 | 7 | _ | |a 10.1002/alz.13012 |2 doi |
| 024 | 7 | _ | |a pmid:36905286 |2 pmid |
| 024 | 7 | _ | |a 1552-5260 |2 ISSN |
| 024 | 7 | _ | |a 1552-5279 |2 ISSN |
| 024 | 7 | _ | |a altmetric:143756763 |2 altmetric |
| 037 | _ | _ | |a DZNE-2023-00670 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Platen, Moritz |0 P:(DE-2719)9001238 |b 0 |e First author |u dzne |
| 245 | _ | _ | |a Impact of low-value medications on quality of life, hospitalization and costs - A longitudinal analysis of patients living with dementia. |
| 260 | _ | _ | |a Hoboken, NJ |c 2023 |b Wiley |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1697111603_28730 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a This study aimed to analyze the impact of low-value medications (Lvm), that is, medications unlikely to benefit patients but to cause harm, on patient-centered outcomes over 24 months.This longitudinal analysis was based on baseline, 12 and 24 months follow-up data of 352 patients with dementia. The impact of Lvm on health-related quality of life (HRQoL), hospitalizations, and health care costs were assessed using multiple panel-specific regression models.Over 24 months, 182 patients (52%) received Lvm at least once and 56 (16%) continuously. Lvm significantly increased the risk of hospitalization by 49% (odds ratio, confidence interval [CI] 95% 1.06-2.09; p = 0.022), increased health care costs by €6810 (CI 95% -707€-14,27€; p = 0.076), and reduced patients' HRQoL (b = -1.55; CI 95% -2.76 to -0.35; p = 0.011).More than every second patient received Lvm, negatively impacting patient-reported HRQoL, hospitalizations, and costs. Innovative approaches are needed to encourage prescribers to avoid and replace Lvm in dementia care.Over 24 months, more than every second patient received low-value medications (Lvm). Lvm negatively impact physical, psychological, and financial outcomes. Appropriate measures are needed to change prescription behaviors. |
| 536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 7 | |a Alzheimer's disease |2 Other |
| 650 | _ | 7 | |a dementia |2 Other |
| 650 | _ | 7 | |a health care costs |2 Other |
| 650 | _ | 7 | |a health care resources |2 Other |
| 650 | _ | 7 | |a health-related quality of life |2 Other |
| 650 | _ | 7 | |a hospitalization |2 Other |
| 650 | _ | 7 | |a low-value care |2 Other |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Quality of Life |2 MeSH |
| 650 | _ | 2 | |a Health Care Costs |2 MeSH |
| 650 | _ | 2 | |a Hospitalization |2 MeSH |
| 650 | _ | 2 | |a Dementia: drug therapy |2 MeSH |
| 700 | 1 | _ | |a Flessa, Steffen |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Teipel, Stefan |0 P:(DE-2719)2000026 |b 2 |u dzne |
| 700 | 1 | _ | |a Rädke, Anika |0 P:(DE-2719)9001134 |b 3 |u dzne |
| 700 | 1 | _ | |a Scharf, Annelie |0 P:(DE-2719)9001251 |b 4 |u dzne |
| 700 | 1 | _ | |a Mohr, Wiebke |0 P:(DE-2719)9001321 |b 5 |u dzne |
| 700 | 1 | _ | |a Buchholz, Maresa |0 P:(DE-2719)9002138 |b 6 |u dzne |
| 700 | 1 | _ | |a Hoffmann, Wolfgang |0 P:(DE-2719)2000040 |b 7 |u dzne |
| 700 | 1 | _ | |a Michalowsky, Bernhard |0 P:(DE-2719)2810763 |b 8 |e Last author |u dzne |
| 773 | _ | _ | |a 10.1002/alz.13012 |g p. alz.13012 |0 PERI:(DE-600)2201940-6 |n 10 |p 4520 - 4531 |t Alzheimer's and dementia |v 19 |y 2023 |x 1552-5260 |
| 856 | 4 | _ | |u https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.13012 |
| 856 | 4 | _ | |u https://pub.dzne.de/record/258697/files/DZNE-2023-00670.pdf |y OpenAccess |
| 856 | 4 | _ | |u https://pub.dzne.de/record/258697/files/DZNE-2023-00670.pdf?subformat=pdfa |x pdfa |y OpenAccess |
| 909 | C | O | |o oai:pub.dzne.de:258697 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 0 |6 P:(DE-2719)9001238 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 2 |6 P:(DE-2719)2000026 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 3 |6 P:(DE-2719)9001134 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 4 |6 P:(DE-2719)9001251 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 5 |6 P:(DE-2719)9001321 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 6 |6 P:(DE-2719)9002138 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 7 |6 P:(DE-2719)2000040 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 8 |6 P:(DE-2719)2810763 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 914 | 1 | _ | |y 2023 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0 |0 LIC:(DE-HGF)CCBYNCND4 |2 HGFVOC |
| 915 | _ | _ | |a DEAL Wiley |0 StatID:(DE-HGF)3001 |2 StatID |d 2022-11-11 |w ger |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2022-11-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2022-11-11 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b ALZHEIMERS DEMENT : 2022 |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-10-25 |
| 915 | _ | _ | |a IF >= 10 |0 StatID:(DE-HGF)9910 |2 StatID |b ALZHEIMERS DEMENT : 2022 |d 2023-10-25 |
| 920 | 1 | _ | |0 I:(DE-2719)1510600 |k AG Hoffmann |l Translational Health Care Research |x 0 |
| 920 | 1 | _ | |0 I:(DE-2719)1510100 |k AG Teipel |l Clinical Dementia Research (Rostock /Greifswald) |x 1 |
| 920 | 1 | _ | |0 I:(DE-2719)1510800 |k AG Thyrian |l Interventional Health Care Research (IHCR) |x 2 |
| 920 | 1 | _ | |0 I:(DE-2719)5000067 |k AG Michalowsky ; AG Michalowsky |l AG Michalowsky |x 3 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-2719)1510600 |
| 980 | _ | _ | |a I:(DE-2719)1510100 |
| 980 | _ | _ | |a I:(DE-2719)1510800 |
| 980 | _ | _ | |a I:(DE-2719)5000067 |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|